Skip to main content
. Author manuscript; available in PMC: 2018 May 9.
Published in final edited form as: HIV Clin Trials. 2017 Jul;18(4):164–173. doi: 10.1080/15284336.2017.1370059

Table 2. Development of Genotypic Resistance at Week 48.

Number of Subjects (% of RAP; % of All Subjects)
Resistance Substitution Development EVG/COBI/FTC/TDF (n=289) ATV+RTV+FTC/TDF (n=286) All (n=575)
Resistance Analysis Population (RAP) 18 (6.2%) 21 (7.3%) 39 (6.8%)
Subjects who resuppressed HIV-1 RNA to <50 copies/mL while on study drugs 11 (61.1%; 3.8%) 9 (42.9%; 3.1%) 20 (51.3%; 3.5%)
Developed Resistance Substitutions to Study Drugs 0 3 (14.3%; 1.0%) 3 (7.7%; 0.5%)
 M184V/I in RT 0 3 (14.3%; 1.0%) 3 (7.7%; 0.5%)